BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Biocon Biologics and Viatris Inc. Receive Historic Approval for First Interchangeable Biosimilar Semglee(r) (insulin glargine-yfgn injection) for the Treatment of Diabetes. BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meetings
Hold Biocon: target of Rs 400: ICICI Direct
ICICI Direct recommended hold rating on Biocon with a target price of Rs 400 in its research report dated July 23, 2021. Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Biocon Biologics Partners with Adagio Therapeutics to Advance Antibody for the Prevention and Treatment of COVID-19 BIOCON LTD. - 532523 - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Biocon Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Change in Directorate
Re-appointment of Directors and Auditors of the Company. Biocon Ltd - 532523 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Scrutinizer''s report and Voting results Biocon Ltd - 532523 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings of 43rd Annual General Meeting of the Company.
Earnings Call for Q1FY22 of Biocon
Conference Call with Biocon Management and Analysts on Q1FY22 Performance and Outlook. Listen to the full earnings transcript.
Biocon net profit falls 35% to Rs 108 crore in Apr-Jun
Consolidated revenue of the company stood at Rs 1,807.8 crore for the quarter under consideration. It was at Rs 1,712.1 crore for the same period a year ago.